Reduced contractility and impaired desmosome assembly in isogenic iPS...
Reduced contractility and impaired desmosome assembly in isogenic iPS cell-derived cardiomyocytes (left: bright-field; right: fluorescence image). Scale bar: 50 μm

Image source: Inoue et al., Stem Cell Reports 2022 (CC BY 4.0)

Cardiology insights

Lab-grown heart cells 'mimic' disease in vitro

In a new study, researchers from Osaka University report that heart cells from a patient with an inherited heart disease called arrhythmogenic cardiomyopathy do not contract correctly when grown in the laboratory, and that replacing the mutated gene responsible for this effect fixes this defect.

Arrhythmogenic cardiomyopathy occurs due to mutations in genes involved in desmosomes, which form ‘welds’ between cells that help them communicate and move in a coordinated way. One of these genes, PKP2, encodes a protein known as plakophilin-2 that is crucial to maintaining heart cell structure. “Previous studies carried out in cardiomyocytes have shown that mutations in PKP2 play a pathological role in arrhythmogenic cardiomyopathy,” says lead author of the study Hiroyuki Inoue. “However, the cells used in those experiments were derived from healthy individuals and were not assessed for contractile function.” 

The research was published in Stem Cell Reports.

These findings suggest that our cardiomyocyte cell lines recapitulate the pathology of arrhythmogenic cardiomyopathy and provide a rapid and convenient platform for developing gene-based therapies for this disease

Shuichiro Higo

To investigate how cells derived from patients behave in the laboratory, the researchers first took a blood sample from a young patient with arrhythmogenic cardiomyopathy, induced some of the blood cells to become stem cells, and then differentiated these stem cells into heart cells. They then modified this original batch of heart cells into three different cell lines with precisely adjusted PKP2 expression based on how many mutated or intact copies of the gene were present. “The cells with two mutated copies of PKP2 clearly exhibited reduced contractility and impaired desmosome assembly due to plakophilin-2 deficiency,” explains senior author Shuichiro Higo. “These effects were also observed in cells with only one mutated copy of PKP2, although they were less severe.” 

Replacing the mutated PKP2 with an intact copy of the gene repaired the defects in both cell contraction and desmosome assembly, which the researchers were able to observe using a time-lapse approach and fluorescently labeled desmosomes. “These findings suggest that our cardiomyocyte cell lines recapitulate the pathology of arrhythmogenic cardiomyopathy and provide a rapid and convenient platform for developing gene-based therapies for this disease,” says Higo. 

Given that PKP2 is the most common gene associated with arrhythmogenic cardiomyopathy, and that PKP2 mutations can lead to severe disease, new therapeutic approaches could help halt disease progression. The findings from this study suggest that gene replacement therapy could be a valuable way of treating patients with this condition and the cell lines created in this study are a viable model to test new therapies for arrhythmogenic cardiomyopathy on. 


Source: Osaka University

25.01.2022

Read all latest stories

Related articles

Photo

Repairing heart muscle with stem cells

Trial run for tissue engineered 'heart patch'

For the first time, engineered heart muscle (EHM) from human induced pluripotent stem cells (iPSCs) will be used to treat patients with heart failure. After regulatory approval, recruitment of the…

Photo

Cardiology research

Can't sleep? Why heart patients should take insomnia seriously

Sleep problems could hint at a heightened risk of heart disease, caution experts at the ESC Preventive Cardiology 2022 congress.

Photo

In heart disease

Lab-grown pig heart tissue could replace animals research

A way to replicate what happens inside the heart after cardiac arrest could open new avenues for the study of heart regeneration whilst reducing the use of live animals in research.

Related products

Alsachim – Dosinaco anticoagulant reagent kit (RUO)

Clinical Chemistry

Alsachim – Dosinaco anticoagulant reagent kit (RUO)

Alsachim, a Shimadzu Group Company
Canon – Alphenix Core

Single Plane

Canon – Alphenix Core

Canon Medical Systems Europe B.V.
Shimadzu – LCMS-8060NX (RUO)

Mass Spectrometry

Shimadzu – LCMS-8060NX (RUO)

Shimadzu Europa GmbH
Subscribe to Newsletter